Beranda › Kanker Kolon › Virginia › Arlington
Uji klinis Kanker Kolon di Arlington, VA
15 studi untuk Kanker Kolon mencari peserta di lokasi sekitar Arlington (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma
Menerima pesertaFase 1/2
- NEXT Virginia, Fairfax · 11 mi jauhnya
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
Menerima pesertaFase 3
- Virginia Cancer Specialists, PC ( Site 0069), Fairfax · 11 mi jauhnya
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
Menerima pesertaFase 1
- ALX Center 2, Fairfax · 11 mi jauhnya
A Study of PHN-012 in Patients With Advanced Solid Tumors
Menerima pesertaFase 1
- PHN-012-001 Site, Fairfax · 11 mi jauhnya
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Menerima pesertaFase 3
- Virginia Cancer Specialists, PC, Arlington
- Virginia Cancer Specialists, PC, Fairfax · 11 mi jauhnya
- Virginia Cancer Specialists, PC, Reston · 14 mi jauhnya
- dan 1 lainnya
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Menerima pesertaFase 1/2
- NEXT Oncology Virginia, Fairfax · 11 mi jauhnya
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Menerima pesertaFase 1/2
- Next Oncology Virginia Cancer Specialist, Fairfax · 11 mi jauhnya
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
Menerima peserta
- Kaiser Permanente Tysons Corner Medical Center, McLean · 5 mi jauhnya
- Kaiser Permanente-Burke Medical Center, Burke · 11 mi jauhnya
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Menerima pesertaFase 2/3
- Kaiser Permanente Tysons Corner Medical Center, McLean · 5 mi jauhnya
- Kaiser Permanente-Burke Medical Center, Burke · 11 mi jauhnya
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer
Menerima pesertaFase 1
- NEXT Oncology, Fairfax · 11 mi jauhnya
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Menerima pesertaFase 1
- NEXT Virginia, Fairfax · 11 mi jauhnya
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Menerima pesertaFase 1
- Research Site, Fairfax · 11 mi jauhnya
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Menerima pesertaFase 1
- NEXT Oncology Virginia, Fairfax · 11 mi jauhnya
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Menerima pesertaFase 1/2
- Next Oncology Virginia, Fairfax · 11 mi jauhnya
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
Menerima pesertaFase 1/2
- NEXT, Virginia, Fairfax · 11 mi jauhnya
Uji klinis Kanker Kolon di kota lain
- Boston, MA22 studi
- New York City, NY22 studi
- Houston, TX20 studi
- Nashville, TN16 studi
- Los Angeles, CA16 studi
- St. Louis, MO15 studi
- Chicago, IL14 studi
- Baldwin Park, CA14 studi
- San Antonio, TX14 studi
- Tampa, FL13 studi
- Baltimore, MD13 studi
- Washington, DC12 studi
Studi lain di Arlington
- Kanker Paru Non-Sel Kecil104 studi
- Kanker Metastatik53 studi
- Kanker Kolorektal52 studi
- Kanker (semua jenis)48 studi
- Kanker Payudara46 studi
- Kanker Ovarium46 studi
- Kanker Paru41 studi
- Kanker Endometrium39 studi
- Kanker Pankreas33 studi
- Karsinoma Sel Skuamosa Kepala dan Leher26 studi
- Kanker Paru Sel Kecil23 studi
- Kanker Payudara Triple-Negatif20 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.